Researcher ties corporate money to favorable drug reviews

The Milbank Quarterly has published a study that may put Sunshine skeptics on edge: the New York Times reports that author Genevieve Pham-Kanter found that FDA advisory panel committee members were more likely to vote in favor of a drug if they had financial ties to just one drugmaker and were part of the panel in charge of reviewing that company's drug.

The Times says Pham-Kanter's assessment of the voting behavior and financial connections of around 1,400 advisory panel members showed that having more than one industry benefactor diluted the inclination to vote in favor of a given treatment.


Next Article in Channel